The brand name for Wegovy — and what it means for your treatment choice

Why the same drug carries different brand names

Pharmaceutical companies often seek separate marketing authorisations for the same molecule when it has genuinely distinct licensed uses. Semaglutide is licensed for two separate clinical purposes in the UK: managing type 2 diabetes and managing weight. Novo Nordisk registered Ozempic for diabetes and Wegovy for weight loss. The difference is not cosmetic. The licensed doses differ, the patient populations differ, and the regulatory reviews that sit behind each authorisation are separate. When a prescriber writes for Wegovy, they are working within the weight-management licence; when they write for Ozempic, they are working within the diabetes licence.

This also explains why Ozempic is not an appropriate route to weight-loss treatment, even though it contains the same active ingredient. The clinical and legal distinction between Wegovy and Ozempic is one our prescribers explain regularly, and it is worth understanding before you start any conversation with a clinician. Prescribing Ozempic off-licence for weight loss (without the full clinical framework that surrounds Wegovy) is not the same thing as being properly assessed for weight management treatment.

There is a third brand worth knowing: Rybelsus, oral semaglutide at lower doses (3 mg, 7 mg and 14 mg), licensed solely for type 2 diabetes. It is a quite different product from the Wegovy tablet, which escalates to a 25 mg maintenance dose and holds a separate weight-management licence. The names on the packaging are doing real clinical work. The medical name behind Wegovy (semaglutide) connects all of these, but the brand name tells you which licence applies.

What the Wegovy name covers now

Wegovy has broadened considerably as a treatment since it first reached the UK. The original form is a once-weekly subcutaneous injection, with doses escalating from 0.25 mg up to a 2.4 mg maintenance dose, typically over around sixteen weeks. In January 2026 a higher maintenance dose of 7.2 mg was authorised; on 14 April 2026 the MHRA approved a dedicated single-dose 7.2 mg pen (one pre-set weekly injection) for adults with a BMI of 30 or above. That approval, confirmed in the MHRA's announcement on GOV.UK, makes Wegovy's injectable range the widest it has ever been.

Then in June 2026 the UK became the first country in Europe to license an oral form of Wegovy, a once-daily tablet with a 25 mg maintenance dose, taken first thing in the morning before food or drink. This is a meaningful option for anyone who is hesitant about injections. Trial data from the OASIS 4 study showed an average weight reduction of around 13.6% over 64 weeks versus placebo; among participants who adhered fully to treatment the figure was closer to 17%. You can read more about the full Wegovy treatment overview to see how the injection and tablet forms compare in practice.

The brand name, in short, now covers both an injectable and an oral route, all within the weight-management licence, all containing semaglutide, and all requiring a valid prescription following clinical assessment.

Choosing between semaglutide and the alternative: what the names can't tell you

If you have been researching weight-loss treatment options you will have come across Mounjaro alongside Wegovy. Mounjaro is the brand name for tirzepatide, a different molecule made by Eli Lilly. Where semaglutide activates one gut-hormone receptor (GLP-1), tirzepatide activates two (GLP-1 and GIP). That dual action is reflected in the trial evidence: in the SURMOUNT-5 head-to-head study, published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight loss than semaglutide 2.4 mg over 72 weeks. The 7.2 mg Wegovy dose narrows that gap, though head-to-head data at the higher semaglutide dose is still accumulating.

None of this means one is categorically right and the other is not. The choice depends on your health history, how well you tolerate each medicine's side-effect profile, which is licensed for your specific BMI and circumstances, and what your prescriber thinks is appropriate after reviewing your full picture. A brand name tells you the active ingredient and the manufacturer; it does not tell you which treatment fits your biology. For context on what private treatment costs across both options, the Wegovy price page sets out the honest market picture, and if you want to explore the broader range of weight-loss treatments available, that is a good starting point too.

The other names for Wegovy (its generic name semaglutide, its INN, the way it appears in pharmacist records) are worth understanding if you are transferring between providers or checking a prescription. Our guide to the generic name for Wegovy covers that in full, as does the overview of all the names Wegovy goes by in clinical and everyday use. If you have seen the term used differently somewhere and want to check it, this page clarifies what the other name for Wegovy is and in what context each version appears.

One practical note: if you are planning ahead for treatment and wondering about timing, orders placed with nume by 12 pm Monday to Friday are dispatched the same day once clinically approved, arriving by DPD the next working day. Bank holidays and the days just before Christmas are worth factoring in if your supply timing matters.

When you are ready to find out whether Wegovy or any other licensed weight-management treatment is suitable for you, the best next step is a clinical conversation. Check your eligibility with our prescribers, the consultation is free, and a GPhC-registered Independent Prescriber reviews every assessment personally.